Oral Sirolimus Treatment for HRAS-Related Epidermal Nevus Syndrome.
Shea M, Fang MM, Kenny L, Wu MD, Funk T
Pediatric DermatologyIn the feed 7 Aug 2026, published online 6 Aug 2026, issue 2026 Aug 06, added to PubMed 7 Aug 2026
Topics: Skin cancer & tumorsGenetic skin diseaseChildren
Abstract
This is the case of a 10-year-old female with HRAS-related epidermal nevus syndrome with extensive and severe cutaneous involvement treated with oral sirolimus. The patient had progressively enlarging verrucous periorbital plaques involving the eyelids, resulting in lagophthalmos and threatening vision. Oral sirolimus rapidly improved the cutaneous lesions and resolved the lagophthalmos. This case of a patient treated with oral sirolimus for HRAS-related epidermal nevus syndrome suggests that therapies targeting the mTOR pathway may indirectly affect the RAS/MAPK pathway.
Abstract from PubMed
PMID 42563420 · DOI 10.1111/pde.70339